Novartis’ immunology drug Cosentyx (secukinumab) notched its sixth indication, gaining U.S. approval as a hidradenitis suppurativa (HS) therapy, the drugmaker said this week. The regulatory OK makes ...

Cosentyx (secukinumab) is a prescription drug that’s used to treat conditions such as plaque psoriasis and psoriatic arthritis. Cosentyx is given as an injection under the skin or as an IV infusion.

The FDA has approved Cosentyx® (secukinumab; Novartis) for the treatment of adults with active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. The Food and ...

Exton, Pennsylvania, Jan. 10, 2024 (GLOBE NEWSWIRE) -- In late October 2023, the FDA granted approval to Novartis' Cosentyx (secukinumab) for treating hidradenitis suppurativa (HS), marking it as the ...

The digital press release with multimedia content can be accessed here: Basel, March 06, 2017 - Novartis announced today a new analysis showing that moderate-to-severe psoriasis patients treated with ...

cosentyx article Cosentyx is the first and only fully-human interleukin-17A (IL-17A) antagonist. In the SCALP study, patients with moderate to severe psoriasis lesions of the scalp (n=102) were ...

Among its dozen FDA approvals for a variety of autoimmune disorders, AbbVie’s Humira has plenty of competition in most of its indications. In the debilitating skin condition hidradenitis suppurativa ...

Please provide your email address to receive an email when new articles are posted on . This approval makes Cosentyx the first interleukin-17A inhibitor and second biologic approved for hidradenitis ...

Novartis has unveiled long-term data indicating that its psoriasis drug Cosentyx is safe and effective for at least five years. Novartis has unveiled long-term data indicating that its psoriasis drug ...

It’s two years since Novartis got its Cosentyx IL-17 drug approved for the spinal disease ankylosing spondylitis, and the Swiss pharma company has new data that it hopes will allow it to compete more ...

In laying out their respective plans Monday to launch new direct-to-patient (DTP) platforms paring down the prices of popular medicines in the U.S., Novartis and Boehringer Ingelheim are falling in ...